RxDoctor Payments Data

Sumeet Anand, MD

Internal Medicine · West Islip, NYNPI 1902896764

Payments from drug & device makers

$3,250in general payments, 2019–2025

Across 141 payments — averaging $23.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$743
  • Amgen$268
  • AstraZeneca$258
  • GSK$255
  • Abbott$236
  • Merck$186
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$3,250100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,250 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$862,443
Medicare patients
462
Services billed
9,691

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide142$232,418
EliquisApixaban98$128,311
JardianceEmpagliflozin78$114,773
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$70,258
JanuviaSitagliptin Phosphate41$63,376
RybelsusSemaglutide32$61,216
ProliaDenosumab32$53,904
FarxigaDapagliflozin Propanediol35$47,525
XareltoRivaroxaban24$35,082
EntrestoSacubitril/Valsartan19$29,840
WegovySemaglutide11$26,549
Breo ElliptaFluticasone/Vilanterol28$23,906
VascepaIcosapent Ethyl31$17,743
VraylarCariprazine Hcl11$15,402
Tresiba Flextouch U-100Insulin Degludec20$15,322

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Wegovy$163$320,183185 claims
PfizerEliquis$168$128,31198 claims
Boehringer IngelheimJardiance$19$114,77378 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$255$104,52981 claims
MerckJanuvia$186$63,37641 claims
AmgenProlia$268$53,90432 claims
AstraZenecaFarxiga$258$47,52535 claims
NovartisEntresto$35$29,84019 claims
AbbVieVraylar, Linzess, Synthroid$743$27,85975 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in West Islip

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →